+

WO1997000883A1 - Composes regulateurs de la meiose - Google Patents

Composes regulateurs de la meiose Download PDF

Info

Publication number
WO1997000883A1
WO1997000883A1 PCT/DK1996/000271 DK9600271W WO9700883A1 WO 1997000883 A1 WO1997000883 A1 WO 1997000883A1 DK 9600271 W DK9600271 W DK 9600271W WO 9700883 A1 WO9700883 A1 WO 9700883A1
Authority
WO
WIPO (PCT)
Prior art keywords
meiosis
compound
general formula
hydrogen
compound according
Prior art date
Application number
PCT/DK1996/000271
Other languages
English (en)
Inventor
Frederik Christian GRØNVALD
Peter Faarup
Erling Guddal
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to AU61226/96A priority Critical patent/AU6122696A/en
Publication of WO1997000883A1 publication Critical patent/WO1997000883A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Definitions

  • the present invention relates to pharmacologically active compounds and to their use as medicaments. More particularly it has been found that the compounds of the invention can be used for regulating the meiosis.
  • Meiosis is the unique and ultimate event of germ cells on which sexual reproduction is based. Meiosis comprises two meiotic divisions. During the first division, exchange between maternal and paternal genes take place before the pairs of chromosomes are separated into the two daughter cells. These contain only half the number (1n) of chromosomes and 2c DNA. The second meiotic division proceeds without a DNA synthesis. This division therefore results in the formation of the haploid germ cells with only 1 c DNA.
  • the meiotic events are similar in the male and female germ cells, but the time schedule and the differentiation processes which lead to ova and to spermatozoa differ profoundly.
  • All female germ cells enter the prophase of the first meiotic division early in life, often before birth, but all are arrested as oocytes later in the prophase (dictyate state) until ovulation after puberty.
  • the female has a stock of oocytes which is drawn upon until the stock is exhausted.
  • Meiosis in females is not completed until after fertilisation, and results in only one ovum and two abortive polar bodies per germ cell.
  • only some of the male germ cells enter meiosis from puberty and leave a stem population of germ cells throughout life. Once initiated, meiosis in the male cell proceeds without significant delay and produces four spermatozoa.
  • MAS meiosis activating substance
  • MPS meiosis preventing substance
  • novel, stable compounds with interesting pharmacological properties.
  • the compounds of the invention are useful for regulating the meiosis in oocytes and in male germ cells.
  • R 1 , R 2 and R 3 independently, are hydrogen or methyl; R 4 and R 5 are either hydrogen or together they designate an additional bond between the carbon atoms to which they are bound.
  • the present invention relates to a compound of the general formula (I) wherein R 1 is hydrogen.
  • the present invention relates to a compound of the general formula (I) wherein R 1 is methyl.
  • the present invention relates to a compound of the general formula (I) wherein R 2 is hydrogen.
  • the present invention relates to a compound of the general formula (I) wherein R 2 is methyl.
  • the present invention relates to a compound of the general formula (I) wherein R 3 is hydrogen.
  • the present invention relates to a compound of the general formula (I) wherein R 3 is methyl.
  • the present invention relates to a compound of the general formula (I) wherein R 4 and R5 are both hydrogen.
  • the present invention relates to a compound of the general formula (I) wherein R 4 and R5 together designate an additional double bond between the carbon atoms to which they are bound.
  • the present invention relates to the use of a compound of the general formula (I) in the manufacture of a medicament.
  • the present invention relates to the use of a compound of the general formula (I) in the manufacture of a medicament for use in the regulation of meiosis.
  • the expression "regulating the meiosis” is understood to indicate that the compounds can be used for stimulating the meiosis in vitro, in vivo, and ex vivo.
  • the present invention relates to the use of a compound of the general formula (I) in the regulation of the meiosis of oocytes or male germ cells.
  • the present invention relates to a method of regulating the meiosis in a mammalian germ cell which method comprises administering an effective amount of a compound of the general formula (I) above to a germ cell in need of such a treatment.
  • the compounds of the present invention will induce resumption of meiosis in oocytes as well as in male germ cells.
  • the existence of a meiosis inducing substance in nature has been known for some time. However, until recently the identity of the meiosis inducing substance or substances has been unknown.
  • the compounds of the general formula (I) are used to stimulate the meiosis.
  • the compounds of the general formula (I) are used to stimulate the meiosis in humans.
  • the compounds of formula (I) are promising as new fertility regulating agents without the usual side effect on the somatic cells which are known from the hitherto used hormonal contraceptives which are based on estrogens and/or gestagens.
  • a meiosis inducing substance can be administered so as to prematurely induce resumption of meiosis in oocytes while they are still in the growing follicle, before the ovulatory peak of gonadotropins occurs.
  • the resumption of the meiosis can, for example, be induced a week after the preceding menstruation has ceased.
  • the resulting overmature oocytes are then most likely not to be fertilised. The normal menstrual cycle is not likely to be affected.
  • a meiosis inducing substance of the general formula (I) can be used in the treatment of certain cases of infertility in females, including women, by administration thereof to females who, due to an insufficient own production of MIS, are unable to produce mature oocytes. Also, when in vitro fertilisation is performed, better results can be achieved, when a meiosis inducing substance of the general formula (I) is added to the medium in which the oocytes are kept. Also, when infertility in males, including men, is caused by an insufficient own production of the meiosis inducing substance administration of a meiosis inducing substance of the general formula (I) can be used for relieving the problem.
  • the route of administration of the compositions containing a compound of formula (I) may be any route which effectively transports the active compound to its site of action.
  • compositions which comprises at least one compound of formula (I) in connection with a phar ⁇ maceutically acceptable carrier.
  • a pharmaceutical composition which comprises at least one compound of formula (I) in connection with a phar ⁇ maceutically acceptable carrier.
  • such compositions are preferably in the form of capsules or tablets.
  • the pharmaceutical compositions may comprise carriers, diluents, abso ⁇ tion enhancers, preservatives, buffers, agents for adjusting the osmotic pressure, tablet disintegrating agents and other ingredients which are conventionally used in the art.
  • solid carriers are magnesium carbonate, magnesium stearate, dextrin, lactose, sugar, talc, gelatine, pectin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting waxes and cocoa butter.
  • Liquid compositions include sterile solutions, suspensions and emulsions. Such liquid compositions may be suitable for injection or for use in connection with ex vivo and in vitro fertilisation.
  • the liquid compositions may contain other ingredients which are conventionally used in the art, some of which are mentioned in the list above.
  • composition for transdermal administration of a compound of this invention may be provided in the form of a patch and a composition for nasal administration may be provided in the form of a nasal spray in liquid or powder form.
  • the dose of a compound of the invention to be used will be determined by a physician and will depend, inter alia, on the particular compound employed, on the route of administration and on the purpose of the use.
  • the compounds of the general formula (I) can be synthesised by methods known per se.
  • Examples of preferred compounds of the general formula (I) are the following:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé régulateur de la méiose, représenté par la formule générale (I) dans laquelle R?1, R2 et R3¿ sont indépendamment hydrogène ou méthyle et R4 et R5 sont l'un et l'autre hydrogène ou désignent ensemble une liaison additionnelle entre les atomes de carbone auxquels ils sont liés.
PCT/DK1996/000271 1995-06-23 1996-06-20 Composes regulateurs de la meiose WO1997000883A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61226/96A AU6122696A (en) 1995-06-23 1996-06-20 Meiosis regulating compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0729/95 1995-06-23
DK72995 1995-06-23

Publications (1)

Publication Number Publication Date
WO1997000883A1 true WO1997000883A1 (fr) 1997-01-09

Family

ID=8096873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1996/000271 WO1997000883A1 (fr) 1995-06-23 1996-06-20 Composes regulateurs de la meiose

Country Status (3)

Country Link
AU (1) AU6122696A (fr)
WO (1) WO1997000883A1 (fr)
ZA (1) ZA965332B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050066A1 (fr) * 1999-02-24 2000-08-31 Novo Nordisk A/S Traitement de l'infecondite
WO2000050065A1 (fr) * 1999-02-24 2000-08-31 Novo Nordisk A/S Traitement de l'infecondite

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000235A1 (fr) * 1994-06-23 1996-01-04 Novo Nordisk A/S Derives du type sterol utilises pour reguler la meiose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000235A1 (fr) * 1994-06-23 1996-01-04 Novo Nordisk A/S Derives du type sterol utilises pour reguler la meiose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. CHEM. SOC. PERKIN TRANS., Volume 1, 1983, MARIO ANASTASIA, "A New Route to Steroid Ring-c Aromatization from 7-Oxygenated Steroids", page 587 - page 590. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050066A1 (fr) * 1999-02-24 2000-08-31 Novo Nordisk A/S Traitement de l'infecondite
WO2000050065A1 (fr) * 1999-02-24 2000-08-31 Novo Nordisk A/S Traitement de l'infecondite
US6281013B1 (en) * 1999-02-24 2001-08-28 Novo Nordisk A/S Treatment of Infertility
US6585982B1 (en) 1999-02-24 2003-07-01 Nna/S Treatment of infertility

Also Published As

Publication number Publication date
ZA965332B (en) 1997-01-23
AU6122696A (en) 1997-01-22

Similar Documents

Publication Publication Date Title
EP0857173B1 (fr) Composes regulateurs de la meiose
US5830757A (en) Stimulation of Meiosis
RU2194510C2 (ru) Применение соединений стерина для получения лекарственного средства, регулирующего мейоз, и способ регуляции мейоза
US6645953B2 (en) Meiosis regulating compounds
US6486145B2 (en) Meiosis regulating compounds
WO1999061010A2 (fr) TRAITEMENT DE L'INFERTILITE PAR DES COMPOSES STIMULANT LA PRODUCTION D'AMPc, SEULS OU ASSOCIES A AU MOINS UN COMPOSE STIMULANT LA MEIOSE
EP1077992B1 (fr) Utilisation de composes regulateurs de la meiose
WO1997000883A1 (fr) Composes regulateurs de la meiose
WO2001062260A2 (fr) Amelioration d'un taux d'implantation
US20030153808A1 (en) Implantation rate using ff-mas
AU759344B2 (en) 22S-hydroxycholesta-8, 14-diene derivatives with meiosis regulating activity
AU4498299A (en) Meiosis regulating compounds
MXPA00009505A (en) TREATMENT OF INFERTILITY WITH cAMP-INCREASING COMPOUNDS ALONE OR IN COMBINATION WITH AT LEAST ONE MEIOSIS-STIMULATING COMPOUND
ZA200107387B (en) Unsaturated cholestane derivatives and their use for the preparation of meiosis regulating medicaments.
EP1514874A1 (fr) Composés thiomorpholinosteroides, leur utilisation pour la préparation de médicaments régulant la meiose et un procédé de leur préparation
MXPA97006565A (es) Estimulacion de meiosis
US20050222098A1 (en) Regulation of meiosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载